Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I 211At-NpG-PSMA Radioligand Therapy in Castration-Resistant Prostate Cancer
jRCT2021250018Phase 1Recruiting
- Start
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 211At-NpG-PSMA in prostate cancer (PCa). Started Jan 2026; status: recruiting.
02
Drugs
211At-NpG-PSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2021250018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250018.